Piper Sandler Maintains Neutral on RxSight, Lowers Price Target to $8
Benzinga Newsdesk 12 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Adam Maeder maintains RxSight (NASDAQ:RXST) with a Neutral and lowers the price target from $10 to $8.
Piper Sandler analyst Adam Maeder maintains RxSight (NASDAQ:RXST) with a Neutral and lowers the price target from $10 to $8.